UNSPSC 51182704: Glyburide/metformin

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class HS502. This VA Drug Class (HS502) classifies this compound as belonging to the group ORAL HYPOGLYCEMIC AGENTS, ORAL.

UNSPSC 51182704 Glyburide/metformin is a Commodity code that in recent state and local procurement shows little activity aligned with its nominal pharmaceutical scope. The single recent opportunity tagged under this code — Seminole County, Florida's IFB 60459723LAS — solicits naloxone and drug deactivation systems, a public health emergency-response product category unrelated to the antidiabetic combination drug the code nominally describes. The mismatch suggests either a cataloging error in the county's tagging or a broader misalignment between the code's definition and how it is applied in practice for state and local health department purchasing.

Seminole County, Florida posted the naloxone and drug deactivation systems IFB on June 30, 2026, with a response deadline of July 26, 2023, seeking 1,900 units of naloxone and 800 drug deactivation systems annually on a two-year contract with a one-year renewal option, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. Vendors must bear all shipping and delivery costs, maintain drug-free workplace and E-Verify compliance, and carry workers' compensation and commercial general liability insurance. The procurement was potentially FEMA-funded and included a three-month probationary termination clause. Beyond this single opportunity, the source does not report additional recent state or local solicitations under this code, limiting visibility into whether glyburide/metformin itself or related diabetes-management pharmaceuticals are being actively procured through state and local channels at present.